References
- Steinhorn R H, Farrow K N. Pulmonary hypertension in the neonate. Neoreviews 2007; 8: e14–21
- Walsh M C, Stork E K. Persistent pulmonary hypertension of the newborn. Clin Perinatol 2001; 28: 609–627
- Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336: 597–604
- Clark R H, Kueser T J, Walker M W, Southgate W M, Huckaby J L, Perez J A, Roy B J, Keszler M, Kinsella J P. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342: 469–474
- Kelly L K, Porta N FM, Goodman D, Carroll C L, Steinhorn R H. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002; 141: 830–832
- Kaapa P, Koivisto M, Ylikorkala O, Kouvalainen K. Prostacyclin in the treatment of neonatal pulmonary hypertension. J Pediatr 1985; 107: 951–953
- Shekerdemian L S, Ravn H B, Penny D J. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Resp Crit Care Med 2002; 165: 1098–1102
- Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: 2398–2403
- Kumar S. Indian doctor in protest after using Viagra to save ‘blue babies’. BMJ 2002; 325: 181
- Travadi J N, Patole S K. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review. Pediatr Pulmonol 2003; 36: 529–535
- Chaudari M, Vogel M, Wright C, Smith J, Haworth S G. Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy. Arch Dis Child Fetal Neonatal Ed 2005; 90: F527–528
- Baquero H, Soliz A, Neira F, Venegas M E, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. Pediatrics 2006; 117: 1077–1083
- Moreno L, Losada B, Cogolludo A, Lodi F, Lugnier C, Villamor E, Moro M, Tamargo J, Pérez-Vizcaíno F. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: Activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. Pediatr Res 2004; 56: 563–570
- Atz A M, Wessel D L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91: 307–310
- Juliana A E, Abbad F C. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: Successful treatment with sildenafil. Eur J Pediatr 2005; 164: 626–629